Lentivirus Pseudotyped with SARS-CoV-2 Spike Glycoprotein, South Africa Variant

Catalog #: EG-342
Size
100 µl
Catalog #:
$798.00
Size
1 ml
Catalog #:
$5000.00
Product Description
Product Name Lentivirus Pseudotyped with SARS-CoV-2 Spike Glycoprotein, HexaPro Variant, South African Variant
Catalog Number EG-342
Description Lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein (Wuhan-Hu-1, GenBank: QHD43416.1, South African variant, B.1.351), stabilized as a trimer (HexaPro variant) with mutations (RRAR682–685GSAS, F817P, A892P, A899P, A942P, K986P, V987P, K417N, E484K, N501Y) to maintain an antigenically optimal prefusion conformation, produced in HEK293T cells, purified by ultracentrifugation, expressing EGFP as a reporter.
Mutations RRAR682–685GSAS, F817P, A892P, A899P, A942P, K986P, V987P, K417N, E484K, N501Y
Source HEK293T cells
Reporter EGFP
Applications
  • Screening SARS-CoV-2 neutralizing antibodies
  • Assessing vaccine efficacy
Titer >1 × 107 RFU/mL or >1 × 105 TU/mL
Storage -80°C
Shipping Dry ice
References
  • Zost, S. J., et al. (2020). Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein. Scientific Reports, 10, 19076. doi:10.1038/s41598-020-76135-w.
  • Starr, T. N., et al. (2021). Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science, 371(6531), 850–854. doi:10.1126/science.abf9302.
Product Documents
DatasheetEG-342 Product Datasheet
Download PDF
Related Products